Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer

Ilir Agalliu, E. Karlins, E. M. Kwon, L. M. Iwasaki, A. Diamond, E. A. Ostrander, J. L. Stanford

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Studies of families who segregate BRCA2 mutations have found that men who carry disease-associated mutations have an increased risk of prostate cancer, particularly early-onset disease. A study of sporadic prostate cancer in the UK reported a prevalence of 2.3% for protein-truncating BRCA2 mutations among patients diagnosed at ages ≤55 years, highlighting the potential importance of this gene in prostate cancer susceptibility. To examine the role of protein-truncating BRCA2 mutations in relation to early-onset prostate cancer in a US population, 290 population-based patients from King County, Washington, diagnosed at ages <55 years were screened for germline BRCA2 mutations. The coding regions, intron-exon boundaries, and potential regulatory elements of the BRCA2 gene were sequenced. Two distinct protein-truncating BRCA2 mutations were identified in exon 11 in two patients. Both cases were Caucasian, yielding a mutation prevalence of 0.78% (95% confidence interval (95%CI) 0.09-2.81%) and a relative risk (RR) of 7.8 (95%CI 1.8-9.4) for early-onset prostate cancer in white men carrying a protein-truncating BRCA2 mutation. Results suggest that protein-truncating BRCA2 mutations confer an elevated RR of early-onset prostate cancer. However, we estimate that <1% of early-onset prostate cancers in the general US Caucasian population can be attributed to these rare disease-associated BRCA2 mutations.

Original languageEnglish (US)
Pages (from-to)826-831
Number of pages6
JournalBritish Journal of Cancer
Volume97
Issue number6
DOIs
StatePublished - Sep 11 2007
Externally publishedYes

Fingerprint

BRCA2 Gene
Germ-Line Mutation
BRCA2 Protein
Prostatic Neoplasms
Mutation
Exons
Confidence Intervals
Population
Rare Diseases
Introns

Keywords

  • BRCA2 gene
  • Early-onset disease
  • Prostate cancer
  • Protein-truncating BRCA2 mutations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Agalliu, I., Karlins, E., Kwon, E. M., Iwasaki, L. M., Diamond, A., Ostrander, E. A., & Stanford, J. L. (2007). Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer. British Journal of Cancer, 97(6), 826-831. https://doi.org/10.1038/sj.bjc.6603929

Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer. / Agalliu, Ilir; Karlins, E.; Kwon, E. M.; Iwasaki, L. M.; Diamond, A.; Ostrander, E. A.; Stanford, J. L.

In: British Journal of Cancer, Vol. 97, No. 6, 11.09.2007, p. 826-831.

Research output: Contribution to journalArticle

Agalliu, I, Karlins, E, Kwon, EM, Iwasaki, LM, Diamond, A, Ostrander, EA & Stanford, JL 2007, 'Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer', British Journal of Cancer, vol. 97, no. 6, pp. 826-831. https://doi.org/10.1038/sj.bjc.6603929
Agalliu, Ilir ; Karlins, E. ; Kwon, E. M. ; Iwasaki, L. M. ; Diamond, A. ; Ostrander, E. A. ; Stanford, J. L. / Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer. In: British Journal of Cancer. 2007 ; Vol. 97, No. 6. pp. 826-831.
@article{4499d1454679434f95d48a7827d9e280,
title = "Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer",
abstract = "Studies of families who segregate BRCA2 mutations have found that men who carry disease-associated mutations have an increased risk of prostate cancer, particularly early-onset disease. A study of sporadic prostate cancer in the UK reported a prevalence of 2.3{\%} for protein-truncating BRCA2 mutations among patients diagnosed at ages ≤55 years, highlighting the potential importance of this gene in prostate cancer susceptibility. To examine the role of protein-truncating BRCA2 mutations in relation to early-onset prostate cancer in a US population, 290 population-based patients from King County, Washington, diagnosed at ages <55 years were screened for germline BRCA2 mutations. The coding regions, intron-exon boundaries, and potential regulatory elements of the BRCA2 gene were sequenced. Two distinct protein-truncating BRCA2 mutations were identified in exon 11 in two patients. Both cases were Caucasian, yielding a mutation prevalence of 0.78{\%} (95{\%} confidence interval (95{\%}CI) 0.09-2.81{\%}) and a relative risk (RR) of 7.8 (95{\%}CI 1.8-9.4) for early-onset prostate cancer in white men carrying a protein-truncating BRCA2 mutation. Results suggest that protein-truncating BRCA2 mutations confer an elevated RR of early-onset prostate cancer. However, we estimate that <1{\%} of early-onset prostate cancers in the general US Caucasian population can be attributed to these rare disease-associated BRCA2 mutations.",
keywords = "BRCA2 gene, Early-onset disease, Prostate cancer, Protein-truncating BRCA2 mutations",
author = "Ilir Agalliu and E. Karlins and Kwon, {E. M.} and Iwasaki, {L. M.} and A. Diamond and Ostrander, {E. A.} and Stanford, {J. L.}",
year = "2007",
month = "9",
day = "11",
doi = "10.1038/sj.bjc.6603929",
language = "English (US)",
volume = "97",
pages = "826--831",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer

AU - Agalliu, Ilir

AU - Karlins, E.

AU - Kwon, E. M.

AU - Iwasaki, L. M.

AU - Diamond, A.

AU - Ostrander, E. A.

AU - Stanford, J. L.

PY - 2007/9/11

Y1 - 2007/9/11

N2 - Studies of families who segregate BRCA2 mutations have found that men who carry disease-associated mutations have an increased risk of prostate cancer, particularly early-onset disease. A study of sporadic prostate cancer in the UK reported a prevalence of 2.3% for protein-truncating BRCA2 mutations among patients diagnosed at ages ≤55 years, highlighting the potential importance of this gene in prostate cancer susceptibility. To examine the role of protein-truncating BRCA2 mutations in relation to early-onset prostate cancer in a US population, 290 population-based patients from King County, Washington, diagnosed at ages <55 years were screened for germline BRCA2 mutations. The coding regions, intron-exon boundaries, and potential regulatory elements of the BRCA2 gene were sequenced. Two distinct protein-truncating BRCA2 mutations were identified in exon 11 in two patients. Both cases were Caucasian, yielding a mutation prevalence of 0.78% (95% confidence interval (95%CI) 0.09-2.81%) and a relative risk (RR) of 7.8 (95%CI 1.8-9.4) for early-onset prostate cancer in white men carrying a protein-truncating BRCA2 mutation. Results suggest that protein-truncating BRCA2 mutations confer an elevated RR of early-onset prostate cancer. However, we estimate that <1% of early-onset prostate cancers in the general US Caucasian population can be attributed to these rare disease-associated BRCA2 mutations.

AB - Studies of families who segregate BRCA2 mutations have found that men who carry disease-associated mutations have an increased risk of prostate cancer, particularly early-onset disease. A study of sporadic prostate cancer in the UK reported a prevalence of 2.3% for protein-truncating BRCA2 mutations among patients diagnosed at ages ≤55 years, highlighting the potential importance of this gene in prostate cancer susceptibility. To examine the role of protein-truncating BRCA2 mutations in relation to early-onset prostate cancer in a US population, 290 population-based patients from King County, Washington, diagnosed at ages <55 years were screened for germline BRCA2 mutations. The coding regions, intron-exon boundaries, and potential regulatory elements of the BRCA2 gene were sequenced. Two distinct protein-truncating BRCA2 mutations were identified in exon 11 in two patients. Both cases were Caucasian, yielding a mutation prevalence of 0.78% (95% confidence interval (95%CI) 0.09-2.81%) and a relative risk (RR) of 7.8 (95%CI 1.8-9.4) for early-onset prostate cancer in white men carrying a protein-truncating BRCA2 mutation. Results suggest that protein-truncating BRCA2 mutations confer an elevated RR of early-onset prostate cancer. However, we estimate that <1% of early-onset prostate cancers in the general US Caucasian population can be attributed to these rare disease-associated BRCA2 mutations.

KW - BRCA2 gene

KW - Early-onset disease

KW - Prostate cancer

KW - Protein-truncating BRCA2 mutations

UR - http://www.scopus.com/inward/record.url?scp=34548570038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548570038&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6603929

DO - 10.1038/sj.bjc.6603929

M3 - Article

VL - 97

SP - 826

EP - 831

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 6

ER -